Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch1 is an effector of Akt and hypoxia in melanoma development
Barbara Bedogni, … , Amato J. Giaccia, Marianne Broome Powell
Barbara Bedogni, … , Amato J. Giaccia, Marianne Broome Powell
Published October 16, 2008
Citation Information: J Clin Invest. 2008;118(11):3660-3670. https://doi.org/10.1172/JCI36157.
View: Text | PDF
Research Article Oncology

Notch1 is an effector of Akt and hypoxia in melanoma development

  • Text
  • PDF
Abstract

Melanomas are highly aggressive neoplasms resistant to most conventional therapies. These tumors result from the interaction of altered intracellular tumor suppressors and oncogenes with the microenvironment in which these changes occur. We previously demonstrated that physiologic skin hypoxia contributes to melanomagenesis in conjunction with Akt activation. Here we show that Notch1 signaling is elevated in human melanoma samples and cell lines and is required for Akt and hypoxia to transform melanocytes in vitro. Notch1 facilitated melanoma development in a xenograft model by maintaining cell proliferation and by protecting cells from stress-induced cell death. Hyperactivated PI3K/Akt signaling led to upregulation of Notch1 through NF-κB activity, while the low oxygen content normally found in skin increased mRNA and protein levels of Notch1 via stabilization of HIF-1α. Taken together, these findings demonstrate that Notch1 is a key effector of both Akt and hypoxia in melanoma development and identify the Notch signaling pathway as a potential therapeutic target in melanoma treatment.

Authors

Barbara Bedogni, James A. Warneke, Brian J. Nickoloff, Amato J. Giaccia, Marianne Broome Powell

×

Figure 1

Notch1 is elevated in melanoma.

Options: View larger image (or click on image) Download as PowerPoint
Notch1 is elevated in melanoma.
(A) HEY1 expression levels in normal ski...
(A) HEY1 expression levels in normal skin, benign nevi, and primary melanoma tumor samples. Boxes denote interquartile range; lines denote median; whiskers denote first and fourth quartiles, excluding outliers (dots). Melanoma vs. nevi, melanoma vs. skin, and melanoma vs. combined benign samples, P < 0.001; skin vs. nevi, P < 0.005; Student’s t test for all comparisons. (B) Western blot analysis of congenital nevus (Cong nev) and melanoma samples. The double band in the upper panel refers to TM-Notch1 (TM) and Notch1-NIC (NIC). The same samples were also probed with a Notch1-NIC–specific antibody. The β-actin was used as loading control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts